Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (6): 953-957    DOI: 10.12891/ceog4977.2019
Original Research Previous articles | Next articles
Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness
J. Namkung1, Y.W. Kim1, J.Y. Kim2, H.B. Kim3, H.Y. Kim4, E.J. Park5, *(), H.K. Sun6
1Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, Korea
2Department of Pathology, The Catholic University of Korea, Seoul, Korea
3Department of Obstetrics and Gynecology, Hallym University College of Medicine, Seoul, Korea
4Department of Obstetrics and Gynecology, Busan, Korea
5Department of Obstetrics and Gynecology, Eulji University. Seoul, Korea
6Kosin University Graduate School, Busan, Korea
Download:  PDF(292KB)  ( 254 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose of Investigation: The aim of the current study is to assess the prognostic value of the lymphocyte-monocyte ratio (LMR) in patients with uterine sarcoma. Materials and Methods: The authors examined the LMR as a prognostic variable in a cohort of 66 patients with uterine sarcoma who underwent surgical resection. Patients were categorized into two groups based on the LMR using cut-off values determined by receiver operating characteristic curve (ROC) analysis. They assessed the effect of the LMR on progression-free survival (PFS) and validated the LMR as independent predictor of survival. Results: Using data from the whole cohort, the optimized LMR cut-off value selected using the ROC curve was 5.86 for PFS. The LMR-low and LMR-high groups included 45 (68.2%) and 21 (31.8%) patients, respectively. The five-year PFS rates in the LMR-low and LMR-high groups were 69.0% and 94.4%, respectively (p= 0.024). Via multivariate analysis, the authors identified FIGO stage, residual tumor after surgery, and LMR as the most valuable prognostic factors affecting PFS (p = 0.039, p = 0.018, and p = 0.043, respectively). Conclusion: The LMR is an independent prognostic factor affecting the PFS of patients with uterine sarcoma.

Key words:  Lymphocytes      Monocytes      Uterine neoplasms      Uterine sarcoma     
Published:  10 December 2019     
*Corresponding Author(s):  EUN JOO PARK     E-mail:  pej3119@eulji.ac.kr

Cite this article: 

J. Namkung, Y.W. Kim, J.Y. Kim, H.B. Kim, H.Y. Kim, E.J. Park, H.K. Sun. Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 953-957.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4977.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I6/953

[1] C.E. Bedient, D. Rodriguez, N. Sidell, C. Roberts, S.C. Schutte. Alterations in the invasive properties of peripheral blood monocytes from patients with endometriosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 60-65.
No Suggested Reading articles found!